Clinical Trial Detail

NCT ID NCT02693535
Title TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors American Society of Clinical Oncology
Indications

Advanced Solid Tumor

multiple myeloma

B-cell lymphoma

Therapies

Cobimetinib + Vemurafenib

Regorafenib

Pembrolizumab

Temsirolimus

Dasatinib

Pertuzumab + Trastuzumab

Ipilimumab + Nivolumab

Crizotinib

Palbociclib

Sunitinib

Olaparib

Cetuximab

Age Groups: child senior adult

Additional content available in CKB BOOST